Amgen (AMGN) continues to generate attention in the biotech industry as a leading player. The company's Q4 performance is eagerly awaited by Wall Street, expecting a growth in earnings due to its increased quarterly dividend to $2.38. Amgen's recent stock movements show a mix of gains and dips that reflect the volatility of the market, but it remains a strong momentum and value stock. Based on its positive financial results for Q4 2024 and the projected Q1 2025 dividend, various market players, including Ibex Wealth Advisors, Crews Bank & Trust, and others, are investing or increasing their shares in Amgen.
There is high anticipation for Amgen's weight loss drug, Maritide, despite not meeting expectations in a Phase 2 study. The FDA approved the extended use of its colorectal cancer therapy Lumakras. Moreover, it's noteworthy that the company is announcing a significant $1 billion expansion in manufacturing in North Carolina, which signifies potentially increased productivity and a bullish outlook. Thus overall, the company's market performance, innovative healthcare solutions, and growth strategies maintain its attractiveness to investors.
Amgen AMGN News Analytics from Thu, 05 Sep 2024 07:00:00 GMT to Sat, 01 Feb 2025 14:24:40 GMT -
Rating 5
- Innovation 8
- Information 7
- Rumor -3
